These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 19177029)
1. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Huang SW; Chen HS; Wang XQ; Huang L; Xu DL; Hu XJ; Huang ZH; He Y; Chen KM; Xiang DK; Zou XM; Li Q; Ma LQ; Wang HF; Chen BL; Li L; Jia YK; Xu XM Pharmacogenet Genomics; 2009 Mar; 19(3):226-34. PubMed ID: 19177029 [TBL] [Abstract][Full Text] [Related]
2. Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement. Kim HS; Lee SS; Oh M; Jang YJ; Kim EY; Han IY; Cho KH; Shin JG Pharmacogenet Genomics; 2009 Feb; 19(2):103-12. PubMed ID: 19077919 [TBL] [Abstract][Full Text] [Related]
3. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Miao L; Yang J; Huang C; Shen Z Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045 [TBL] [Abstract][Full Text] [Related]
4. A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation. Wei M; Ye F; Xie D; Zhu Y; Zhu J; Tao Y; Yu F Thromb Haemost; 2012 Jun; 107(6):1083-91. PubMed ID: 22534826 [TBL] [Abstract][Full Text] [Related]
5. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846 [TBL] [Abstract][Full Text] [Related]
6. Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients. You JH; Wong RS; Waye MM; Mu Y; Lim CK; Choi KC; Cheng G J Thromb Thrombolysis; 2011 Jan; 31(1):113-8. PubMed ID: 20585834 [TBL] [Abstract][Full Text] [Related]
7. Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients. Liang R; Li L; Li C; Gao Y; Liu W; Hu D; Sun Y J Thromb Thrombolysis; 2012 Jul; 34(1):120-5. PubMed ID: 22528326 [TBL] [Abstract][Full Text] [Related]
8. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. Cen HJ; Zeng WT; Leng XY; Huang M; Chen X; Li JL; Huang ZY; Bi HC; Wang XD; He YL; He F; Zhou RN; Zheng QS; Zhao LZ Br J Clin Pharmacol; 2010 Aug; 70(2):234-40. PubMed ID: 20653676 [TBL] [Abstract][Full Text] [Related]
9. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients. Ekladious SM; Issac MS; El-Atty Sharaf SA; Abou-Youssef HS Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801 [TBL] [Abstract][Full Text] [Related]
11. Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response. Shalia KK; Doshi SM; Parikh S; Pawar PP; Divekar SS; Varma SP; Mehta R; Doctor T; Shah VK; Saranath D J Assoc Physicians India; 2012 Dec; 60():34-8. PubMed ID: 23781667 [TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin. Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031 [TBL] [Abstract][Full Text] [Related]
13. Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients. Choi JR; Kim JO; Kang DR; Yoon SA; Shin JY; Zhang X; Roh MO; Hong HJ; Wang YP; Jo KH; Lee KS; Yun HJ; Oh YS; Yoo KD; Jeon HG; Lee YS; Kang TS; Park HJ; Chung MW; Kang JH J Hum Genet; 2011 Apr; 56(4):290-5. PubMed ID: 21326313 [TBL] [Abstract][Full Text] [Related]
15. Genetic and clinical determinants influencing warfarin dosing in children with heart disease. Nguyen N; Anley P; Yu MY; Zhang G; Thompson AA; Jennings LJ Pediatr Cardiol; 2013 Apr; 34(4):984-90. PubMed ID: 23183958 [TBL] [Abstract][Full Text] [Related]
16. The pharmacogenetics of the response to warfarin in Chinese. Lam MP; Cheung BM Br J Clin Pharmacol; 2012 Mar; 73(3):340-7. PubMed ID: 22023024 [TBL] [Abstract][Full Text] [Related]
17. Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation. Cho HJ; On YK; Bang OY; Kim JW; Huh W; Ko JW; Kim JS; Lee SY Clin Ther; 2011 Oct; 33(10):1371-80. PubMed ID: 21981797 [TBL] [Abstract][Full Text] [Related]
18. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. Limdi NA; Wiener H; Goldstein JA; Acton RT; Beasley TM Blood Cells Mol Dis; 2009; 43(1):119-28. PubMed ID: 19297219 [TBL] [Abstract][Full Text] [Related]
19. Estimation of the warfarin dose with a pharmacogenetic refinement algorithm in Chinese patients mainly under low-intensity warfarin anticoagulation. Xu Q; Xu B; Zhang Y; Yang J; Gao L; Zhang Y; Wang H; Lu C; Zhao Y; Yin T Thromb Haemost; 2012 Dec; 108(6):1132-40. PubMed ID: 23015069 [TBL] [Abstract][Full Text] [Related]
20. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Tham LS; Goh BC; Nafziger A; Guo JY; Wang LZ; Soong R; Lee SC Clin Pharmacol Ther; 2006 Oct; 80(4):346-55. PubMed ID: 17015052 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]